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Summary
Maximal expiratory flow rates such as peak expi-
ratory flow rate (PEFR), rates at 25%, 50% and 75%
of vital capacity (VE max 25%, VE max 50%, VE max
75%) and forced expiratory flow during the middle half
of forced vital capacity (FEF 25-75%) were recorded
in 23 patients with tropical eosinophilia (TE) before
and after treatment. The mean values of all flow rates
were significantly lower (P< 0.001) in untreated TE
patients compared to predicted values. After three
weeks’ treatment with diethylcarbamazine, although
there was a significant rise in the mean values of all
  expiratory flow rates (P< 0.05) except VE max 75%
(P> 0.2), all flow rates continued to be significantly
lower (P< 0.01) at one month than predicted values.
Introduction
dyspnoea and nocturnal wheezing, chest xray infiltra-
tes, peripheral blood eosinophilia with absolute counts
of > 2000 cells/cu mm, high serum titres of antifilarial
IgG and a favourable response to DEC. All patients
had symptoms for less than 6 months and none had
received treatment with DEC in the past. Peak expira-
tory flow rate (PEFR), maximal expiratory flow rates
at 25%, 50% and 75% of vital capacity (VE max 25%,
VE max 50% and VE max 75%) and forced expiratory
flow during the middle half of forced vital capacity
(FEF 25-75%) were recorded using Transfer Test
Model C (PK Morgan Ltd, Chatham, UK). This instru-
ment was provided with a Data Dec computer and X
–Y recorder for electronic memory and recording flow
volume loops. The results were printed out after corre-
ction to body temperature and pressure saturated with
water vapour (BTPS).
Studies in patients with untreated tropical eosino-
philia (TE) have revealed that the main pulmonary
function abnormality is a reduction in single-breath
transfer factor (TLCO) (1,2). Transfer factor had signi-
ficant negative correlation with lung eosinophils, su-
ggesting that the eosinophilic inflammation of the
lower respiratory tract may be responsible for the lung
injury. It is also known that there is incomplete reve-
rsal of this abnormality following a standard 3 week
course of diethylcarbamazine (DEC) (5). Since TE
patients present with asthma like symptoms (6),
airway inflammation leading to airflow limitation in
addition to lung parenchymal inflammation (7) is
possible in untreated TE. We have reported reductions
in maximal expiratory rates in untreated TE (8).
However, how this would change with treatment is not
known. The aim of the present study was, therfore,
to assess response of maximal expiratory flow rates
to a standard 3 week course of DEC.
Maximal expiratory flow-volume loops were reco-
rded by asking the subject to take the deepest breath
possible, wrap his mouth tightly around a mouth piece,
and on a given signal to blow out as completely and
rapidly as possible, and finally to inhale fully as fast
as possible taking care to keep his back against the
chair-back all the time (9). At least three consistent
flow-volume loops were obtained from each patient and
the highest value obtained was used for calculation
of PEFR. Values of FEF 25-75%, VE max 25%, VE
max 50% and VE max 75% were derived from the single
best test, and the best test was defined as the one with
the highest value of FEV1 and FVC (10,11). The
predicted values of maximal expiratory flow rates were
obtained from regression equations established in our
laboratory (12).
Materials and methods
All patients were treated with DEC 6 mg/kg daily
for 21 days. Maximal expiratory flow rates were repea-
ted after one month in all patients.
Twenty three patients fulfilling the diagnostic Data are presented as mean+ SD. Statistical ana-
criteria of TE (6) were studied. The diagnosis was based lysis was performed using two-tailed students paired
on the criteria of residence in the filarial endemic area t test. A P value less than 0.05 was considered as
of Madras city, respiratory symptoms such as cough, significant.
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Table 1. Effect of treatment on maximal expiratory flow rates (l/s) in patients with TE (mean + SD)
Predicted Patients with Patients
Variable value TE at TE at
diagnosis one month
(n = 23) (n = 23)
PEFR 6.8±0.7 5.3±1.6 5.8±1.6**
VE max 25% 5.5±0.6   4.1±1.4 4.8±1.2**
VE max 50% 3.8±0.4 2.7±0.9 3.1±1.1**
VE max 75% 1.9±0.3 1.2±0.9 1.4±0.8*
FEF 25-75% 3.9±0.5 2.3±0.9 3.2±0.9**
* No significant change with treatment
** Significant improvement after treatment but still significantly less than predicted values.
Results Discussion
All patients were males and eleven of them were
smokers. The mean (±SD) age was 22.5 ± 5.3 years
(range 15–40 years), height 163.3 ± 6.6 cm and weight
47.4 ±8.3 kg. Since there were no differences in mean
values of expiratory flow rates in smokers and non-
smokers, this factor was not considered separately.
The maximal expiratory flow rates (l/s) before and
after treatment are shown in Table 1. At diagnosis,
the mean PEFR (5.3 ± 1.6), VE max 25% (4.1±1.4),
VE max 50% (2.7 ± 0.9), VE max 75% (1.2 ± 0.9) and
FEF 25-75% (2.8 ± 0.9) were significantly lower than
the predicted values (P< 0.05). Following treatment,
at one month, the mean PEFR (5.8 ± 1.6), VE max
25% (4.8±1.2),VE max 50% (3.1±1.1) and FEF 25-75%
(3.2 ± 0.9) showed a significant rise compared to
pre-treatment values, but VE max 75% (1.4 ± 0.8) did
not show a significant change. However, all flow rates
at one month continued to be significantly lower than
the predicted values (Figure 1).
Figure 1
Previous pulmonary function studies in patients
with untreated TE have shown that the main physiolo-
gical abnormality is a reduced diffusing capacity and
mild to moderate restrictive and obstructive ventilato-
ry defects (1,2,5,6). They also showed that there was
incomplete reversal of these changes one month after
treatment (2,5). The significant negative correlation
between eosinophil count in bronchoalveolar lavage
fluid and single-breath transfer factor suggests the
possibility that eosinophilic infiltration can cause inju-
ry to lung parenchyma (3,4). The clinical manifesta-
tions of nocturnal wheezing and rhonchi (6,13) along
with mild obstructive ventilatory defect (5,6) suggest
that there is airway inflammation in addition to lung
parenchymal inflammation (7).
It is possible that bronchial inflammation leads
to airway obstruction resulting in reduced expiratory
flow rates in untreated TE. This is further corrobora-
ted by the airway hyperreactivity seen in TE patients
(14). It has been suggested that eosinophilic inflamma-
tion can induce bronchial hyperresponsiveness in bro-
nchial asthma (15). Thus, it appears that eosinophilic
inflammation of the bronchial tree may also be an
important factor in TE along with lung parenchymal
inflammation (7). Symptoms disappeared in most pa-
tients with DEC for 3 weeks (5), and this was associa-
ted with significant improvement in expiratory flow
rates. However, the expiratory flow rates at one month
were significantly lower than the predicted values.
This finding together with the earlier observation of
incomplete reversal of other physiological abnormali-
ties after treatment in TE (5) suggests that inflamma-
tion does not resolve completely with the three week
treatment schedule. A mild chronic inflammation that
persists (16) may be responsible for the significantly
reduced expiratory flow rates at one month. Studies
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are therefore, required to evaluate other treatment
modalities including long term DEC or corticosteroids.
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